IPOGrid
0001966494
IPO filing research

CARGO Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · CRGX

follow-on trading trading Nasdaq Global Select Market EFFECT

CARGO Therapeutics, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: EFFECT on 2025-08-27. Current deal snapshot: exchange Nasdaq Global Select Market.

Filing Timeline

SEC EDGAR
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2025-08-27 · 9999999995-25-002754
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2025-08-27 · 9999999995-25-002752
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows EFFECT and marks the registration effective.
2025-03-21 · 9999999995-25-000733
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2025-03-21 · 9999999995-25-000730
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows 424B3 and confirms the priced prospectus.
Common Stock · Exchange Nasdaq Global Select Market · Ticker CRGX
2024-11-13 · 0001193125-24-256289
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Common Stock · Exchange Nasdaq Global Select Market · Ticker CRGX
2024-08-12 · 0001193125-24-198949
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows 424B3 and marks the registration effective.
2024-06-27 · 9999999995-24-001997
424B3 priced
Final prospectus
Final prospectus filed near launch with final deal terms.
Follows S-1 and confirms the priced prospectus.
6,471,000 shares · Gross proceeds $110,000,000
common · Exchange Nasdaq · Ticker CRGX · Selling stockholders only · Use of proceeds Selling stockholders will bear all commissions and expenses
2024-06-27 · 0001193125-24-170635
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows 424B4 in the pre-IPO sequence.
6,471,000 shares · Gross proceeds $0.00
common · Exchange Nasdaq · Ticker CRGX · Selling stockholders only · Use of proceeds Selling stockholders will bear all costs and expenses
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell therapies for cancer, particularly autologous CAR T-cell treatments. The company is registering 6,471,000 shares of common stock for resale by selling stockholders following a $110M private placement completed in May 2024. The lead program, firicabtagene autoleucel (firi-cel), targets B-cell lymphoma and is advancing to a Phase 2 trial. CARGO is an emerging growth company with a pipeline leveraging proprietary cell engineering platforms to address limitations of current CAR T therapies.
2024-06-17 · 0001193125-24-161818
424B4 priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Price $15.00 · 18,750,000 shares · Gross proceeds $281,250,000
Common stock · Exchange Nasdaq Global Select Market · Ticker CRGX · Over-allotment 2,812,500 · Use of proceeds General corporate purposes · Underwriters J.P. Morgan, Jefferies, TD Cowen
2023-11-13 · 0001193125-23-276087
EFFECT effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows CERT and marks the registration effective.
2023-11-09 · 9999999995-23-003277
CERT inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
Follows 8-A12B in the pre-IPO sequence.
2023-11-09 · 0001354457-23-000825
8-A12B effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows S-1/A and registers the class of securities for exchange listing.
2023-11-07 · 0001193125-23-272404
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Range $15.00 to $17.00 · 18,750,000 shares · Gross proceeds $318,750,000
common · Exchange Nasdaq Global Select Market · Ticker CRGX · Over-allotment 2,812,500 · Use of proceeds general corporate purposes · Underwriters J.P. Morgan, Jefferies, TD Cowen
2023-11-06 · 0001193125-23-270801
S-1/A amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
common stock · Exchange Nasdaq · Ticker CARGO
CARGO Therapeutics, Inc. filed an S-1/A registration statement on November 1, 2023, amending its initial S-1 filing. The amendment solely adds Exhibit 10.2 (a license agreement) without modifying the prospectus. The company is registering shares for an IPO, with details on securities offerings, indemnification provisions, and recent unregistered securities sales. The filing includes corporate governance details, legal opinions, and exhibits related to intellectual property licenses and stock plans.
2023-11-01 · 0001193125-23-268347
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
common stock of CARGO Therapeutics, Inc. · Exchange Nasdaq Global Select Market · Ticker CRGX · Underwriters J.P. Morgan, Jefferies, TD Cowen
2023-10-20 · 0001193125-23-259928
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
2023-10-04 · 0000950123-23-008693
DRS filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
2023-09-01 · 0000950123-23-008431
Comparable Deals

16 comparable deals

Healthcare & Biotech$100-300MLast 18 months
Only 0 strict matches; expanded to 16 using nearest neighbors.
Showing top 8 by similarity.
-8.3%
Median day-1
44%
Above issue
-3.0%
Median week-1
-20.9%
Downside (p10)
Standard Nuclear, Inc. STDN
2026-07-16 $150M Day 1: -8.2% Wk 1: -37.2%
same SIC groupnearby deal sizerecent IPO
Agomab Therapeutics NV AGMB
2026-02-06 $200M Day 1: -8.4% Wk 1: -2.1%
same SICnearby deal sizerecent IPO
Odyssey Therapeutics, Inc. ODTX
2026-05-08 $279M Day 1: -8.8% Wk 1: -3.8%
same SICrecent IPO
Aardvark Therapeutics, Inc. AARD
2026-02-06 $94M Day 1: -20.9% Wk 1: -23.3%
same SIC groupsimilar deal sizerecent IPO
Hemab Therapeutics Holdings, Inc. COAG
2026-05-01 $302M Day 1: +88.9% Wk 1: +43.0%
same SICrecent IPO
Seaport Therapeutics, Inc. SPTX
2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%
same SIC groupnearby deal sizerecent IPO
Avalyn Pharma Inc. AVLN
2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%
same SIC grouprecent IPO
Eikon Therapeutics, Inc. EIKN
2026-02-05 $381M Day 1: -16.7% Wk 1: -19.5%
same SICrecent IPO

Recent News

No recent news stored for this issuer.